Historical rmd News Stories
ResMed Q3 Beat, Noctrix Deal, Stock Near Low +Divs
ResMed delivered a solid Q3 with double-digit revenue growth, margin expansion, strong cash flow and continued buybacks and dividends. Recent strategic moves — a Noctrix acquisition and a planned CFO transition — plus an RBC price-target lift occurred as the stock traded near its 52-week low.
ResMed Expands Indiana Hub; AI Comfort Debut 2026!
ResMed’s recent moves — a new Indiana distribution center, FDA clearance for an AI-driven comfort feature, solid Q2 FY2026 results, and notable insider activity — combine operational execution and product innovation that materially affect RMD’s near-term outlook.
ResMed Dip: CEO Sale, Baird Cuts Price Target Now!
ResMed (RMD) slipped after CEO Michael J. Farrell sold nearly 5,000 shares and Robert W. Baird lowered its price target. This article breaks down the March 11 sell-off, recent analyst movements and the dividend context to help investors weigh near-term noise against underlying fundamentals.
ResMed RMD: Quiet Week, Small Volatility - Update!
ResMed (RMD) saw modest volatility last week with a notable dip on Feb 24 and a partial rebound on Feb 26. There were no material corporate, regulatory, or earnings developments during the period; price moves reflected short-term trading rather than new fundamental information. The company’s durable respiratory-care franchise and progress in AI-enabled devices continue to underpin investor confidence.
ResMed Strengthens Margins; RMD Risks Rise—Q2 Beat
ResMed reported a strong Q2 with revenue up 11%, expanding margins and a $600M+ buyback plan, but near-term headwinds from GLP‑1 therapies, trade probes and competitive shifts inject caution for RMD in the S&P 500.
ResMed Drops After Philips Return Fears; EPS Beat
ResMed shares fell mid‑week after analyst concerns about Philips re‑entering the U.S. CPAP market, despite ResMed posting a beat on Q2 FY2026 EPS and revenue. Diverging analyst price targets and strong underlying fundamentals created the volatility.
RMD Rally: ResMed Up 9% on Renewed Investor Flows!
ResMed (RMD) staged a four-day rebound in early February, climbing from $251.41 to $275.96 as trading volumes ran above 50‑day averages. No new company‑specific catalysts were reported during the week; the move appears driven by investor re-entry and sector strength ahead of potential upcoming corporate events.